Expression data of Pioglitazone-, Rosiglitazone-, GW1929- and vehicle-treated CD4+FoxP3- T cells transduced with Foxp3+Pparg1. Mus musculus

Pioglitazone treatment of CD4+FoxP3- T cells transduced with Pparg and Foxp3 up-regulated a set of genes whose products have been implicated in lipid metabolism pathways. To verify the specificity of this treatment, we performed microarray analysis on Foxp3+Pparg1-transduced CD4+FoxP3- T cells after treatment with other PPARg agonists such as Rosiglitazone (TZD) and GW1929 (non-TZD). Overall design: All gene expression profiles were obtained from highly purified (double-sorted) T cell populations sorted by flow cytometry. To reduce variability, cells from multiple mice were pooled. Triplicates were generated for all groups. Raw data were preprocessed with the RMA algorithm in GenePattern and averaged expression values were used for analysis.

对转导了过氧化物酶体增殖物激活受体γ基因（Pparg）与叉头框蛋白P3（Foxp3）的CD4阳性FoxP3阴性T细胞（CD4+FoxP3- T cells）施以吡格列酮处理后，可上调一组其产物已被证实参与脂质代谢通路的基因。为验证该处理的特异性，我们对经罗格列酮（TZD）、GW1929（非TZD类）等其他过氧化物酶体增殖物激活受体γ（PPARg）激动剂处理后的、转导了Foxp3与过氧化物酶体增殖物激活受体γ1（Pparg1）的CD4阳性FoxP3阴性T细胞开展了微阵列分析。总体实验设计：所有基因表达谱均来源于经流式细胞术分选的高纯度（双次分选）T细胞群。为降低实验变异性，将多只小鼠的细胞进行混合制备。所有实验组均设置3次生物学重复。原始数据通过GenePattern平台中的RMA算法完成预处理，以平均表达值作为后续分析的依据。